首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Letters In Drug Design & Discovery

Letters In Drug Design & Discovery杂志,由Bentham Science Publishers B.V.出版,于2004年创刊,Bimonthly,出版语言English,ISSN:1570-1808,E-ISSN:1875-628X。

投稿咨询
Letters In Drug Design & Discovery
Letters In Drug Design & Discovery
Letters In Drug Design & Discovery
SCI SCIE

杂志介绍

JCR分区
Q4
中科院分区
4区
影响因子
1.6
CiteScore
2.2
期刊收录
SCI、SCIE

Letters In Drug Design & Discovery(中文译名:《药物设计与发现快报》),ISSN:1570-1808,EISSN:1875-628X,是Bentham Science Publishers B.V.出版的国际性学术期刊,创刊于2004年,以Bimonthly形式稳定发行,2026年总发文量约227篇。该刊采用非OA开放访问,学科归属为医学 - 医药化学。该刊是医学、药物化学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达1.6,2025年期刊CiteScore为2.2,2025年期刊自引率约6.2%,在中科院期刊分区体系中位列医学大类4区,在所属学科领域具备高学术影响力与国际认可度。Letters In Drug Design & Discovery长期聚焦医学、药物化学及相关产业的技术应用前沿,平均审稿周期约3.0个月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、药物化学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,IndiaCHINA MAINLAND、Turkey、Iran、Pakistan、Saudi Arabia、Brazil等为核心发文国家与地区;TEHRAN UNIVERSITY OF MEDICAL SCIENCESUNIVERSITY OF KARACHI、ANADOLU UNIVERSITY、IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY、ZHEJIANG UNIVERSITY OF TECHNOLOGY、COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (CSIR) - INDIA、PCSIR LABORATORIES COMPLEX等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
CHEMISTRY, MEDICINAL 药物化学
4区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
CHEMISTRY, MEDICINAL 药物化学
4区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
CHEMISTRY, MEDICINAL 药物化学
4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:CHEMISTRY, MEDICINAL SCIE Q4 60 / 72

17.4

学科:CHEMISTRY, MEDICINAL SCIE Q4 59 / 72

18.75

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:CHEMISTRY, MEDICINAL SCIE Q4 57 / 72

21.5

学科:CHEMISTRY, MEDICINAL SCIE Q4 61 / 72

15.97


中国学者近期发文

1
Matrine protects human glomerular mesangial cells from lipopolysaccharide-induced Injury via the MCP-1/CCR2 axis and TLR4/NF-κB pathway in glomerulonephriti

Author:Wei, Huanbing; Dai, Yunfeng; Gao, Ying; Jia, Weiwei; Li, Ang

Journal: LETTERS IN DRUG DESIGN & DISCOVERY. 2026; Vol. 23, Issue 1, pp. -. DOI: 10.1016/j.lddd.2026.100346

2
Unveiling biomarkers of chemoresistance: CASP1, ENG, and H6PD in 5-Fu-treated colorectal cance

Author:Huang, Xiang; Hua, Long; Ye, Junhao; Zhu, Lijun; Zhu, Yiping

Journal: LETTERS IN DRUG DESIGN & DISCOVERY. 2026; Vol. 23, Issue 1, pp. -. DOI: 10.1016/j.lddd.2026.100375

3
Research progress on the mechanism and intervention strategies of MET protein in regulating the resistance to targeted therapy for EGFR-mutated non-small cell lung cance

Author:Chen, Fanghong; Zhang, Hangyue; Wang, Chengcheng; Liu, Menglan; Gao, Xudong; Wang, Jianxia; Shen, Li

Journal: LETTERS IN DRUG DESIGN & DISCOVERY. 2026; Vol. 23, Issue 1, pp. -. DOI: 10.1016/j.lddd.2026.100357

4
Epigallocatechin gallate impels osteogenic differentiation of human BMSCs by targeting the METTL3/SATB2/Wnt/β-catenin axi

Author:Ren, Qiao; Chen, Kang; Wang, Lin

Journal: LETTERS IN DRUG DESIGN & DISCOVERY. 2025; Vol. 22, Issue 3, pp. -. DOI: 10.1016/j.lddd.2025.100027

5
Efficacy analysis of Salmeterol Xinafoate and Fluticasone Propionate power for inhalation in treating pediatric asthma patient

Author:Zheng, Bojuan; Gao, Lianlian; Zhou, Liang; Li, Jinying; Tian, Liyuan; Yuan, Jie

Journal: LETTERS IN DRUG DESIGN & DISCOVERY. 2025; Vol. 22, Issue 2, pp. -. DOI: 10.1016/j.lddd.2025.100020

6
Puerarin alleviates spinal cord injury by mediating the proliferation and activation of NG2 glial cell

Author:Ye, Ping; Liao, Xinyuan; Zhao, Yin; Zhou, Shengyuan; Guo, Xiang; Yang, Lili; Lv, Bitao

Journal: LETTERS IN DRUG DESIGN & DISCOVERY. 2025; Vol. 22, Issue 2, pp. -. DOI: 10.1016/j.lddd.2025.100011

7
The mechanism of Peilian Ephehuang Prescription in the treatment of simple obesity based on network pharmacology and molecular docking technolog

Author:Wen, Nuan; Gu, Changrui; Zhao, Ying; Ma, Jian

Journal: LETTERS IN DRUG DESIGN & DISCOVERY. 2025; Vol. 22, Issue 2, pp. -. DOI: 10.1016/j.lddd.2025.100019

8
Thymoquinone suppresses cell growth and induces ferroptosis in renal cell carcinoma by reducing SERPINH1 expressio

Author:Luo, Ruiying; Li, Shuang; Wang, Haohao; Zhang, Zuyu; Li, Long; Shang, Panfeng

Journal: LETTERS IN DRUG DESIGN & DISCOVERY. 2025; Vol. 22, Issue 2, pp. -. DOI: 10.1016/j.lddd.2025.100013

9
Exploring the mechanism of Grifolin in inhibiting the malignant progression of colon cancer cells mediated by the PDGFRB/PI3K/ AKT signaling pathway based on bioinformatics analysis and network pharmacolog

Author:Han, Yu; Chen, Yaping; Xiao, Xingchun; Li, Zhong; Shi, Wentai; Lin, Qiling

Journal: LETTERS IN DRUG DESIGN & DISCOVERY. 2025; Vol. 22, Issue 2, pp. -. DOI: 10.1016/j.lddd.2025.100018

10
Glucosamine hinders IL-1f-induced CHON-001 cell injury and inflammation by inhibiting YY1-mediated TLR

Author:Wu, Jianqiang; Zhu, Xuefang

Journal: LETTERS IN DRUG DESIGN & DISCOVERY. 2025; Vol. 22, Issue 1, pp. -. DOI: 10.1016/j.lddd.2025.100003


在线咨询

Letters In Drug Design & Discovery

国际简称:LETT DRUG DES DISCOV参考译名:药物设计与发现快报

年发文量:227 CiteScore:2.2 是否预警:否 Gold OA文章占比:30.21% 研究类文章占比:96.92%

杂志社联系方式:BENTHAM SCIENCE PUBL LTD, EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, SHARJAH, U ARAB EMIRATES, 1200 BR

Letters In Drug Design & Discovery